Approximately 30% of patients with chronic lymphocytic leukemia (CLL) can be grouped into subsets with stereotyped B cell receptor immunoglobulin (BcR IG) displaying remarkable similarity in the heavy complementarity-determining region 3 (VH CDR3). Here, we investigated whether the consensus VH CDR3 sequences from CLL stereotyped subsets can be exploited for immunotherapy approaches.
Exploiting B Cell Receptor Stereotypy to design Tailored Immunotherapy in Chronic Lymphocytic Leukemia / Rovida, Alessandra; Maccalli, Cristina; Scarfò, Lydia; Dellabona, Paolo; Stamatopoulos, Kostas; Ghia, Paolo. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - (2020), p. clincanres.1632.2020. [10.1158/1078-0432.CCR-20-1632]
Exploiting B Cell Receptor Stereotypy to design Tailored Immunotherapy in Chronic Lymphocytic Leukemia
Scarfò, Lydia;Ghia, Paolo
2020-01-01
Abstract
Approximately 30% of patients with chronic lymphocytic leukemia (CLL) can be grouped into subsets with stereotyped B cell receptor immunoglobulin (BcR IG) displaying remarkable similarity in the heavy complementarity-determining region 3 (VH CDR3). Here, we investigated whether the consensus VH CDR3 sequences from CLL stereotyped subsets can be exploited for immunotherapy approaches.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
